Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vardenafil is a small molecule pharmaceutical drug used to treat erectile dysfunction (impotence) in men. It belongs to the class of phosphodiesterase type 5 (PDE5) inhibitors. Vardenafil works by selectively inhibiting the enzyme PDE5, which increases levels of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum during sexual stimulation. This leads to increased blood flow into the penis and facilitates erection. Vardenafil is structurally similar to sildenafil but differs slightly in its molecular structure and pharmacological profile. It is taken orally and has a relatively short duration of action compared to tadalafil but somewhat longer than sildenafil. Developed by Bayer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vardenafil.